Janux Therapeutics Inc (JANX)
39.30
-2.42
(-5.80%)
USD |
NASDAQ |
Jul 02, 16:00
40.00
+0.70
(+1.78%)
After-Hours: 20:00
Janux Therapeutics Research and Development Expense (TTM): 53.13M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 53.13M |
| December 31, 2023 | 54.92M |
| September 30, 2023 | 58.12M |
| June 30, 2023 | 59.96M |
| March 31, 2023 | 59.12M |
| December 31, 2022 | 53.44M |
| September 30, 2022 | 49.18M |
| Date | Value |
|---|---|
| June 30, 2022 | 43.84M |
| March 31, 2022 | 34.50M |
| December 31, 2021 | 26.24M |
| September 30, 2021 | 16.05M |
| June 30, 2021 | 8.481M |
| March 31, 2021 | 4.417M |
| December 31, 2020 | 3.041M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
3.041M
Minimum
Dec 2020
59.96M
Maximum
Jun 2023
37.46M
Average
46.51M
Median
Research and Development Expense (TTM) Benchmarks
| Arvinas Inc | 368.80M |
| Agios Pharmaceuticals Inc | 296.84M |
| Viking Therapeutics Inc | 76.90M |
| Syndax Pharmaceuticals Inc | 185.47M |
| Krystal Biotech Inc | 45.10M |